Indian generic drugmakers may see supply shortages from China if coronavirus drags on - (CNBC via NewsPoints Desk)

  • Industry experts are warning that shortages and potential price increases of generic drugs from India could be in store if the COVID-19 outbreak disrupts suppliers of pharmaceutical ingredients in China past April, as reported by CNBC.

  • According to the news source, India's generic drugmakers, which get nearly 70% of the active pharmaceutical ingredients (APIs) for their medicines from China, say they currently have sufficient API supplies from China to cover their operations for up to about three months.

  • "We are comfortably placed with 8 to 10 weeks of key inventory in place," commented Debabrata Chakravorty, head of global sourcing and supply chain for Lupin, adding that the company does have some local suppliers for ingredients.

  • Daara Patel, secretary general of the Indian Drug Manufacturers Association, which represents over 900 drug producers, said he expects supplies to be disrupted from April, with antibiotics and vitamins likely to be among the hardest hit as India is a major global producer of both.

  • Still, international pharmaceutical companies including Novartis and GlaxoSmithKline have so far predicted minimal disruption in the near term to their supply chain.

  • "Companies are continuously monitoring the situation and are working proactively to prevent and mitigate potential shortages," stated Holly Campbell, spokeswoman for pharmaceutical industry trade group PhRMA.

To read more NewsPoints articles, click here.